 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||||| Ad26.Mos4.HIV / J&J
Trial completion: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Sep 14, 2023
P3, N=3900, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed
- ||| Ad26.Mos4.HIV / J&J
Trial completion date: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - May 31, 2023
P3, N=3900, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Trial completion date: Mar 2024 --> Aug 2023
- |||| Ad26.Mos4.HIV / J&J
Trial primary completion date: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Mar 30, 2023
P3, N=3900, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Mar 2024 --> Aug 2023 Trial primary completion date: Mar 2024 --> Aug 2023
- ||||| Ad26.Mos4.HIV / J&J
Enrollment closed: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Oct 27, 2021
P3, N=3903, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Mar 2024 --> Aug 2023 Recruiting --> Active, not recruiting
- |||| Ad26.Mos4.HIV / J&J
Trial primary completion date: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Aug 18, 2021
P3, N=3800, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2023 --> Mar 2024
- | Ad26.Mos4.HIV / J&J
Trial completion date: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Sep 2, 2020
P3, N=3800, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Jan 2023 --> Mar 2024 Trial completion date: Sep 2023 --> Mar 2024
- | Ad26.Mos4.HIV / J&J
Enrollment open: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - Dec 5, 2019
P3, N=3800, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Sep 2023 --> Mar 2024 Not yet recruiting --> Recruiting
- | Ad26.Mos4.HIV / J&J
New P3 trial: MOSAICO: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (clinicaltrials.gov) - May 28, 2019
P3, N=3800, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.